» Articles » PMID: 30231891

Characteristics of Patients with Thromboembolic Disorders on Warfarin Therapy in Resource Limited Settings

Overview
Publisher Biomed Central
Specialty Health Services
Date 2018 Sep 21
PMID 30231891
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Warfarin is a drug with narrow therapeutic index used in the management of thromboembolic disorders. Several factors affect its plasma concentrations with a resultant risk of toxicity. We examined the database of patients on warfarin therapy in order to establish the factors that affect the stability of INR and correlated them to clinical outcomes in resource limited settings.

Methods: We analysed retrospective data of patients admitted to adult medical wards at Moi Teaching and Referral Hospital (MTRH) in 2015. Inclusion criteria were patients with thromboembolic and related disorders and on warfarin treatment. Derived data included demographics, indications for warfarin use, co-prescribed drugs, co-morbidities, INR measurements, duration of hospital stay and clinical outcomes. Descriptive statistics were used to summarize the data. Pearson's correlation coefficient was used to assess relationships between duration of hospitalization and number of INR tests. Regression splines were used to capture INR trends during the follow up period. Data was analysed using R v. 3.3.1.

Results: A total of 310 patients had thromboembolic disorders, out of which 63 met the study criteria. The median age was 48 years, while the mean number of INR measurements was once every four days. Majority of patients did not achieve stable INR values, with only two having consecutive INR values within therapeutic goal. Patients who died had high INR levels. The median duration of hospital stay was 9 days (IQR: 7.0, 16.5). There was a significant correlation between length of stay in hospital and the number of times that INR were measured (Corr = 0.667, p < 0.001). The two most common indications for warfarin were DVT (64.4%) and atrial fibrillation (24.7%). All the patients had one or more comorbid conditions except for 11 with DVT alone, with cardiovascular diseases and infections being the most frequent, and on concomitant medications, majority of which are known to interact with warfarin.

Conclusions: It was difficult to achieve stable INR under the prevailing conditions despite the frequent tests. The potential factors that may have contributed to the fluctuations include drug-drug interactions, frequency of INR tests, comorbidities and the short duration of hospital stay.

Citing Articles

Warfarin Pharmacogenomics for Precision Medicine in Real-Life Clinical Practice in Southern Africa: Harnessing 73 Variants in 29 Pharmacogenes.

Muyambo S, Ndadza A, Soko N, Kruger B, Kadzirange G, Chimusa E OMICS. 2021; 26(1):35-50.

PMID: 34958284 PMC: 8792494. DOI: 10.1089/omi.2021.0199.


Improving anticoagulation in sub-Saharan Africa: What are the challenges and how can we overcome them?.

Mouton J, Blockman M, Sekaggya-Wiltshire C, Semakula J, Waitt C, Pirmohamed M Br J Clin Pharmacol. 2021; 87(8):3056-3068.

PMID: 33586223 PMC: 8359270. DOI: 10.1111/bcp.14768.

References
1.
Nelson W, Wang L, Baser O, Damaraju C, Schein J . Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation. Int J Clin Pharm. 2014; 37(1):53-9. PMC: 4312387. DOI: 10.1007/s11096-014-0038-3. View

2.
Leung N, Chen A, Yadav P, Gallien J . The Impact of Inventory Management on Stock-Outs of Essential Drugs in Sub-Saharan Africa: Secondary Analysis of a Field Experiment in Zambia. PLoS One. 2016; 11(5):e0156026. PMC: 4882057. DOI: 10.1371/journal.pone.0156026. View

3.
Gitter M, Jaeger T, Petterson T, Gersh B, Silverstein M . Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota. Mayo Clin Proc. 1995; 70(8):725-33. DOI: 10.4065/70.8.725. View

4.
Patel K, Mehdirad A, Lim M, Ferreira S, Mikolajczak P, Stolker J . Beyond warfarin: a patient-centered approach to selecting novel oral anticoagulants for stroke prevention in atrial fibrillation. J Hosp Med. 2014; 9(6):400-6. DOI: 10.1002/jhm.2201. View

5.
Passman R . Time in Therapeutic Range in Warfarin-Treated Patients: Is Very Good Good Enough?. JAMA. 2016; 316(8):872-3. DOI: 10.1001/jama.2016.10402. View